Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 28 от 222

Набира участници

Pilot Trial for WounDx™ Clinical Decision Support Tool

Wounds Wounds and Injuries Extremity Injury Traumatic Wounds and Injuries +3

The purpose of this research is to evaluate the overall use of the WounDx medical device in a clinical setting, such as a hospital. The WounDx device is experimental and not yet approved by the United States Food and Drug Administration (FDA). WounDx uses information about a patient's wound to generate a report that a surgeon may use to help determine when to close or not close the wound. The final decision to close the wound remains with the surgeon. The results from this pilot trial will inform a larger pivotal trial.

Начало: 21.03.2026 Край: 20.09.2026 Възраст: 18–65 г.

United States Henry M. Jackson Foundation for the Advancement of Mili NCT06921707

Набира участници

Training Medical Residents in the Use of the Venous Excess UltraSound (VExUS) Score for Bedside Volume Assessment.

Acute Heart Failure (AHF) Fluid Over-load Congestion Congestion, Venous

This randomized controlled trial evaluates the effectiveness of two training approaches (in-person versus remote) for teaching medical residents to apply the Venous Excess Ultrasound (VExUS) score for bedside volume assessment in patients with acute heart failure. Resident performance will be compared to that of expert physicians certified in abdominal and duplex sonography.

Начало: 20.03.2026 Край: 31.12.2026

Switzerland Insel Gruppe AG, University Hospital Bern NCT07541768

Набира участници

Peri-procedural Hydration to Prevent Acute Kidney Injury After Pulsed Field Ablation for Atrial Fibrillation

Atrial Fibrillation (AF) Acute Kidney Injury

PFA is an emerging non-thermal ablation technology with favorable procedural safety; however, recent studies have raised concerns about peri-procedural hemolysis and subsequent AKI after PFA. This study is a single-center, open-label, randomized controlled trial designed to evaluate whether standardized peri-procedural intravenous hydration can reduce the risk of acute kidney injury (AKI) after pulsed field ablation (PFA) for atrial fibrillation (AF). Eligible adult patients with symptomatic paroxysmal or persistent AF scheduled for PFA will be randomly assigned in a 1:1 ratio to either a standardized hydration strategy or a control strategy without routine prophylactic hydration. The hydration group will receive 0.9% saline at 2 mL/kg/h from entry into the electrophysiology laboratory until 12 hours after the procedure, while the control group will receive no routine preventive hydration and will be treated with fluids only if clinically indicated. The primary outcome is any in-hospital AKI defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary endpoints include in-hospital AKI severity by KDIGO stage, in-hospital persistent moderate-to-severe AKI, in-hospital renal replacement therapy, changes in renal function after the procedure, and clinical outcomes through 30 and 90 days, including all-cause death, persistent AKI, renal replacement therapy, all-cause rehospitalization, and composite major adverse events.

Начало: 20.03.2026 Край: 01.10.2026 Възраст: от 18 г.

China Beijing Anzhen Hospital NCT07490808

Набира участници

A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients

Chronic Rhinosinusitis With Nasal Polyps

This is a prospective, multicenter real-world study to describe the postoperative outcomes and quality of life, disease control and characteristics of patients who underwent surgery, as well as economic burden and post-operative treatment patterns in Chinese patients with CRSwNP recurrence.

Начало: 20.03.2026 Край: 30.08.2027

China AstraZeneca NCT07446738

Набира участници Фаза 1

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Hepatic Impairment

The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.

Начало: 20.03.2026 Край: 04.02.2027 Възраст: 18–85 г.

United States AstraZeneca NCT07546760

Набира участници Фаза 1

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Neisseria Meningitidis Serogroup B

A randomized, double-blinded, positive-controlled clinical trial will be conducted to observe the safety and immunogenicity of DX-104 in adults 18 to 50 years of age.

Начало: 20.03.2026 Край: 01.07.2027 Възраст: 18–50 г. Превенция

Australia Shanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks) NCT07395739

Набира участници

Impact of Cocaine Use and Withdrawal on Sleep

Cocaine Use Disorder

This study investigates how cocaine use and withdrawal affect sleep and circadian rhythms in individuals undergoing inpatient detoxification. Using wearable sleep monitors, actigraphy, questionnaires, and hormonal biomarkers, it aims to capture both objective and subjective changes in sleep across three key stages: active use, early withdrawal, and late withdrawal. The study is unique in its ability to explore sleep microstructure, the circadian system's role via melatonin and cortisol measurements, and the dynamic relationship between subjective sleep perception and objective sleep data. It also examines whether sleep quality may serve as a predictive marker of long-term withdrawal success.

Начало: 19.03.2026 Край: 31.12.2028 Възраст: от 18 г.

France Hôpital le Vinatier NCT07119567

Набира участници

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

Hypoparathyroidism

This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.

Начало: 19.03.2026 Край: 01.01.2028 Възраст: 18–50 г.

United States Ascendis Pharma A/S NCT07264634

Набира участници Фаза 2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Начало: 19.03.2026 Край: 01.04.2029 Възраст: 18–79 г.

Canada, United States Oruka Therapeutics, Inc. NCT07474792

Набира участници

Long-Term Outcomes of Teplizumab in Routine Clinical Care

Type 1 Diabetes

This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.

Начало: 19.03.2026 Край: 29.10.2035

Israel, United States Sanofi NCT07360080

Набира участници

Virtual Reality Cognitive Intervention for Critically Ill Delirium Survivors (VR-Cog)

Intensive Care Unit Delirium Intensive Care Acquired Cognitive Impairment Post Intensive Care Unit Syndrome Virtual Reality Cognitive Training

The purpose of this study is to measure the feasibility, acceptability of virtual reality (VR) brain games and estimate their effect on memory, attention, and mood for ICU survivors. The VR program will be used at home through a headset and hand controls.

Начало: 19.03.2026 Край: 15.07.2027 Възраст: от 50 г.

United States Indiana University NCT07496255

Набира участници Фаза 2

Reversal of Spinal Anesthesia Residual Motor Block Via Intrathecal Catheter

Joint Replacement Surgery

The purpose of this study is to determine the feasibility of administering a predetermined amount of normal saline into the intrathecal or subarachnoid space via a small spinal catheter to reduce or eliminate the effects of previously injected spinal anesthetic following lower extremity orthopedic surgery.

Начало: 19.03.2026 Край: 01.12.2027

United States Beth Israel Deaconess Medical Center NCT07404982

Набира участници Фаза 3

Opioid-Sparing Joint Replacement

Pain Management Opioid Consumption

The goal of this clinical trial is to evaluate whether an opioid-sparing postoperative pain regimen can reduce opioid consumption and maintain effective pain control in adults undergoing anterior total hip arthroplasty for osteoarthritis. The main questions it aims to answer are: * Does an opioid-limited regimen result in lower postoperative opioid use compared with a standard opioid prescription? * Does the opioid-limited regimen provide comparable or improved postoperative pain control and patient satisfaction?

Начало: 19.03.2026 Край: 01.08.2028 Възраст: от 18 г.

United States Emory University NCT07348627

Набира участници Фаза 2/3

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Netherton Syndrome

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

Начало: 19.03.2026 Край: 31.03.2027 Възраст: от 4 г.

United States Quoin Pharmaceuticals NCT07538583

Набира участници

Large Language Model for Understanding and Monitoring Elderly Neurocognition

Dementia

Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. However, these histories can be incomplete, unstructured, or difficult to obtain, making diagnosis more challenging. This study will test LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition), an AI-powered conversation tool designed to help caregivers describe their loved one's symptoms more effectively. By asking structured questions and guiding the conversation, LUMEN can create clear, well-organised reports for memory clinic doctors. This could make assessments quicker, more accurate, and less stressful for families. We will test LUMEN in real-world clinics by asking caregivers and doctors to use it and provide feedback. We want to understand how easy it is to use, whether it could improve the quality of information shared, and how it fits into existing NHS memory clinic processes. We will also run co-production workshops with community groups to ensure the tool is accessible to people from diverse cultural and language backgrounds. This research is exciting because it explores how artificial intelligence can improve dementia care. If successful, LUMEN could enhance the diagnostic process, reduce carer burden, and help more people access dementia support sooner. In the future, this tool could be used nationwide in memory clinics, improving care for thousands of families.

Начало: 19.03.2026 Край: 31.12.2026 Възраст: от 65 г.

United Kingdom Northumbria Healthcare NHS Foundation Trust NCT07347431

Набира участници Фаза 1

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

HIV

This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity). The expectation is that ePGT121v1-LS, whether given alone or with PGDM1400LS and VRC07-523LS, by IV or SC, will be safe in generally healthy adults and that the antibodies will not interfere with each other when used together. Approximately 83 volunteers in overall good health and without HIV-1 will be enrolled into two parts (A and B). Part A has six groups. In Groups 1-3, participants will get ePGT121v1-LS given by IV at one of three dose levels: 5 mg/kg, 20 mg/kg, or 40 mg/kg. In Groups 4-6, participants will receive three antibodies-first ePGT121v1-LS, then PGDM1400LS and VRC07-523LS-given by IV at two separate visits that are 24 weeks apart. The total study duration for participants in Part A is 48 weeks of scheduled clinic visits. Part B has two groups. In Group 7, people will get ePGT121v1-LS as SC shots at two visits 12 weeks apart. Each visit will give a total of 375 mg, split into three injections of 125 mg each. In Group 8, people will also have two visits 12 weeks apart and will receive three antibodies as SC shots in this order: first ePGT121v1-LS (125 mg), then PGDM1400LS (100 mg), and then VRC07-523LS (100 mg). The total study duration for participants in Part B is 24 weeks of scheduled clinic visits.

Начало: 19.03.2026 Край: 30.08.2027 Възраст: 18–55 г.

Peru, United States, Zimbabwe National Institute of Allergy and Infectious Diseases ( NCT07390955

Набира участници Фаза 4

Evaluation Of The Success Rate of NOVAMag® SHIELD

Alveolar Buccal Bone Dehiscences Socket Type 3 Subclass B Socket Type 3 Subclass C

This study hypothesizes that the SHIELD technique, when combined with a suitable bone graft material, enables successful immediate implant placement in Type 3 extraction sockets with buccal bone dehiscence, regardless of the extent of buccal bone loss. Specifically, it is proposed that the regenerative potential of the SHIELD technique is not significantly affected by the degree of buccal bone dehiscence, whether in compromised sockets (ST3 Subclass B, when a buccal dehiscence is present and extending 1/3 to 2/3 of the total length of the alveolus) or severely compromised sockets (ST3 Subclass C, for severe dehiscence passing more than 2/3 of the facial bone of the alveolus). All in all, this study aims to assess the clinical performance of the CE-approved medical device NOVAMag® SHIELD by evaluating its success rate and long-term suitability for the rehabilitation of edentulous regions in routine clinical settings. It further seeks to generate clinically meaningful evidence supporting the safety and efficacy of magnesium-based biomaterials in the management of complex post-extraction defects. In addition, the study investigates the CE-approved self-tapping conical implant VEGA® + to obtain comprehensive clinical data contributing to post-market surveillance and continuous product evaluation.

Начало: 19.03.2026 Край: 30.09.2027

Portugal Egas Moniz - Cooperativa de Ensino Superior, CRL NCT07533110

Набира участници Фаза 1/2

Study in Advanced Solid Tumor Patients

Advanced Solid Tumor

The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.

Начало: 19.03.2026 Край: 17.07.2028 Възраст: от 18 г. Лечение

Australia, United States Callio Therapeutics NCT07300943

Набира участници Фаза 1

Single Ascending Dose Study of HB2198 in Healthy Participants

Healthy Volunteer

Phase 1, single center, randomized, double blind, placebo controlled SAD study assessing safety, tolerability, PK, PD, and immunogenicity of HB2198 after a single IV infusion in healthy adults. Four dose levels will be explored with sentinel participants per cohort. Approximately 32 participants (6 HB2198:2 placebo per cohort) will be followed for \~2 months, with extended follow up if B-cell counts remain suppressed.

Начало: 19.03.2026 Край: 21.08.2026 Възраст: до 55 г. Лечение

Australia Hinge Bio NCT07439263

Набира участници

Functional Outcomes and Control Using Synchron BCI - Canada

Neurologic Disorder ALS Motor Neuron Disease

Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN)

Начало: 18.03.2026 Край: 01.07.2027 Възраст: от 18 г.

Canada Synchron, Inc. NCT07446114

1 … 26 27 28 29 30 … 222